KR950008306B1 - 프로스타글란딘 및 하이드록시-지방산 합성용 조성물의 제조방법 - Google Patents

프로스타글란딘 및 하이드록시-지방산 합성용 조성물의 제조방법 Download PDF

Info

Publication number
KR950008306B1
KR950008306B1 KR1019870004500A KR870004500A KR950008306B1 KR 950008306 B1 KR950008306 B1 KR 950008306B1 KR 1019870004500 A KR1019870004500 A KR 1019870004500A KR 870004500 A KR870004500 A KR 870004500A KR 950008306 B1 KR950008306 B1 KR 950008306B1
Authority
KR
South Korea
Prior art keywords
group
acid
fatty acid
unsaturated fatty
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019870004500A
Other languages
English (en)
Korean (ko)
Other versions
KR870010867A (ko
Inventor
울리히 바이트만 클라우스
Original Assignee
훽스트 아크티엔게젤샤프트
하인리히 벡커, 베른하르트 벡크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훽스트 아크티엔게젤샤프트, 하인리히 벡커, 베른하르트 벡크 filed Critical 훽스트 아크티엔게젤샤프트
Publication of KR870010867A publication Critical patent/KR870010867A/ko
Application granted granted Critical
Publication of KR950008306B1 publication Critical patent/KR950008306B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019870004500A 1986-05-09 1987-05-08 프로스타글란딘 및 하이드록시-지방산 합성용 조성물의 제조방법 Expired - Fee Related KR950008306B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3615710.4 1986-05-09
DE19863615710 DE3615710A1 (de) 1986-05-09 1986-05-09 Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen

Publications (2)

Publication Number Publication Date
KR870010867A KR870010867A (ko) 1987-12-18
KR950008306B1 true KR950008306B1 (ko) 1995-07-27

Family

ID=6300504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870004500A Expired - Fee Related KR950008306B1 (ko) 1986-05-09 1987-05-08 프로스타글란딘 및 하이드록시-지방산 합성용 조성물의 제조방법

Country Status (16)

Country Link
US (1) US5043328A (enExample)
EP (1) EP0244832B1 (enExample)
JP (1) JPS62267222A (enExample)
KR (1) KR950008306B1 (enExample)
AT (1) ATE77549T1 (enExample)
AU (1) AU603574B2 (enExample)
CA (1) CA1302266C (enExample)
DE (2) DE3615710A1 (enExample)
DK (1) DK167518B1 (enExample)
ES (1) ES2051705T3 (enExample)
GR (1) GR3005768T3 (enExample)
HU (1) HU201671B (enExample)
IE (1) IE60273B1 (enExample)
IL (1) IL82459A (enExample)
PT (1) PT84841B (enExample)
ZA (1) ZA873299B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639828B1 (fr) * 1988-12-01 1993-11-05 Lvmh Recherche Utilisation du kaempferol et de certains de ses derives pour la preparation d'une composition cosmetique ou pharmaceutique
DK173585B1 (da) * 1989-11-09 2001-04-02 Asta Medica Ag Anvendelse af alfa-liponsyre til fremstilling af et lægemiddel til bekæmpelse af sygdomme fremkaldt af retrovirus
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US5399584A (en) * 1992-05-05 1995-03-21 The Procter & Gamble Company Use of flavone derivatives for gastroprotection
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
WO1994015464A1 (en) * 1993-01-15 1994-07-21 Abbott Laboratories Structured lipids
SE507682C2 (sv) * 1996-03-29 1998-07-06 Marcin Krotkiewski Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
CA2389236A1 (en) * 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
US6228367B1 (en) * 1999-12-22 2001-05-08 Renew Life, Inc. Food supplement formulation
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
US7098352B2 (en) * 2001-11-16 2006-08-29 Virtus Nutrition Llc Calcium salt saponification of polyunsaturated oils
AU2003247685A1 (en) * 2002-07-02 2004-01-23 Galileo Pharmaceuticals, Inc. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20050164908A1 (en) * 2004-01-23 2005-07-28 Ginsberg Myron D. Neuroprotective complex for treatment of cerebral ischemia and injury
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1765964A4 (en) * 2004-04-30 2007-11-07 SYNTHESIS OF METALLIC SALTS OF MONOVALENT AND DIVALENT POLYUNSATURATED FATTY ACIDS
WO2006054316A1 (en) * 2004-11-16 2006-05-26 Magene Life Sciences Private Limited Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors
US20070082063A1 (en) * 2005-10-11 2007-04-12 Douglas Bibus Risk assessment and correction of membrane damage of the upper GI tract
US8372425B2 (en) * 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
BR112013001609A2 (pt) * 2010-07-22 2017-04-04 Merz Pharma Gmbh & Co Kgaa composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
IN2014DN09065A (enExample) * 2012-04-16 2015-05-22 Rhodia Operations
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
AU2014225619A1 (en) * 2013-03-06 2015-10-15 Rutgers, The State University Of New Jersey Nutritional supplement/feed formula and methods of use thereof to reduce development of Osteochondrosis Dissecans (OCD) lesions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE237029C (enExample) *
FR2197605A1 (en) * 1972-09-06 1974-03-29 Williams John Foodstuff or skin nutrient to combat cholesterolaemia - contains arachidonic acid or gamma linolenic acid or esters and salts thereof
JPS537492B2 (enExample) * 1973-02-12 1978-03-18
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
DE2813814A1 (de) * 1978-03-31 1979-10-18 Boehringer Mannheim Gmbh Hochwirksame, enteral resorbierbare pharmazeutische praeparate
IE53332B1 (en) * 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
EP0087865B1 (en) * 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
FR2522935A1 (fr) * 1982-03-10 1983-09-16 Chevalier Jacques Nouveaux produits a base de lait et de ses derives riches en acides gras polyinsatures et leur procede de preparation
JPS58164508A (ja) * 1982-03-26 1983-09-29 Eisai Co Ltd イソプレニルカルボン酸含有外用組成物
ATE22533T1 (de) * 1982-04-29 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
DE3381777D1 (de) * 1982-12-09 1990-09-06 Advanced Drug Tech Einfach absorbierbare fettsaeureemulsionen.
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB2140806B (en) * 1983-05-28 1987-10-28 Sekimoto Hiroshi Stabilisation of unsaturated fatty acids, fish oils or fish
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
ATE33333T1 (de) * 1984-01-11 1988-04-15 Von Mletzko Armin Dr Diaetetikum.
JPS60184011A (ja) * 1984-03-02 1985-09-19 Itaru Yamamoto 免疫調節剤
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
JPS62187425A (ja) * 1985-10-14 1987-08-15 Michio Nakanishi リノレン酸系化合物含有組成物
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E

Also Published As

Publication number Publication date
ES2051705T3 (es) 1994-07-01
HUT44433A (en) 1988-03-28
PT84841A (de) 1987-06-01
ZA873299B (en) 1987-11-02
ATE77549T1 (de) 1992-07-15
KR870010867A (ko) 1987-12-18
DK167518B1 (da) 1993-11-15
PT84841B (pt) 1990-02-08
GR3005768T3 (enExample) 1993-06-07
DK235687A (da) 1987-11-10
IE871203L (en) 1987-11-09
IE60273B1 (en) 1994-06-29
DE3779958D1 (de) 1992-07-30
EP0244832A3 (en) 1989-11-29
EP0244832B1 (de) 1992-06-24
DE3615710A1 (de) 1987-11-26
IL82459A (en) 1994-07-31
IL82459A0 (en) 1987-11-30
DK235687D0 (da) 1987-05-08
CA1302266C (en) 1992-06-02
EP0244832A2 (de) 1987-11-11
AU603574B2 (en) 1990-11-22
HU201671B (en) 1990-12-28
US5043328A (en) 1991-08-27
JPS62267222A (ja) 1987-11-19
AU7264187A (en) 1987-11-12

Similar Documents

Publication Publication Date Title
KR950008306B1 (ko) 프로스타글란딘 및 하이드록시-지방산 합성용 조성물의 제조방법
McCall et al. Therapeutic potential of fish oil in the treatment of ulcerative colitis
CN102209701B (zh) 异戊二烯基化合物和其方法
JP3537832B2 (ja) 代謝を増強し酸化ストレスを防止するための食物組成物
US4058594A (en) Immuno-suppressive agents
US3993775A (en) Immuno-suppressive agents
McCULLY Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism
JPS61215322A (ja) γ‐リノレン酸またはジホモ‐γ‐リノレン酸の使用方法
WO2010056145A1 (ru) Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
EP0201159A2 (en) Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy
Ruggiero et al. Effect of aging and acetyl-L-carnitine on the lipid composition of rat plasma and erythrocytes
JPS60120995A (ja) 新規アミノ酸誘導体の製法
OLSON The absorption of beta-carotene and its conversion into vitamin A
JPH0647541B2 (ja) 医療用途を有する新規なヘミン錯化合物を製造する方法
JPS58206524A (ja) 抗腫瘍剤
US4587242A (en) Sulfonic resins having a therapeutical activity, preparation thereof and pharmaceutical compositions containing them
EP1153010A1 (en) $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME
US20050245434A1 (en) Oxygenated dibenzo-alpha-pyrone chromoproteins
US20050233942A1 (en) Oxygenated dibenzo-alpha-pyrone chromoproteins
WO2005099739A1 (en) Oxygenated dibenzo-alpha-pyrone chromoproteins
Biagi et al. The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in rat liver under oxidative stress
Tertov et al. Cyclic nucleotides and atherosclerosis: studies in primary culture of human aortic cells
DE69909137T2 (de) Polyungesättigte Fettsäurederivate und deren Verwendung in der Krebsbehandlung
Juan et al. Eicosapentaenoic acid inhibits the release of 14C-prostacyclin from a perfused tissue after incorporation of 14C-prostaglandin precursors
JPH05213985A (ja) ピロールカルボン酸コエンザイムａ誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20020621

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030728

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030728

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000